Abstract:Background: Studies have reported that RNA-binding proteins (RBPs) are dysregulated in multiple cancers and are correlated with the progression and prognosis of disease. However, the functions of RBPs in non-small cell lung cancer (NSCLC) remain unclear. The present study aimed to explore the function of RBPs in NSCLC and their prognostic and therapeutic value. Methods: The mRNA expression profiles, DNA methylation data, gene mutation data, copy number variation data, and corresponding clinical information on NSCLC were downloaded from The Cancer Genome Atlas, Gene Expression Omnibus, and the University of California Santa Cruz Xena databases. The differentially expressed RBPs were identified between tumor and control tissues, and the expression and prognostic value of these RBPs were systemically investigated by bioinformatics analysis. A quantitative polymerase chain reaction (qPCR) was performed to validate the dysregulated genes in the prognostic signature. Results: A prognostic RBP-related signature was successfully constructed based on eight RBPs represented as a risk score using least absolute shrinkage and selection operator (LASSO) regression analysis. The high-risk group had a worse overall survival (OS) probability than the low-risk group (p < 0.001) with 1-, 3-, and 5-year area under the receiver operator characteristic curve values of 0.671, 0.638, and 0.637, respectively. The risk score was associated with the stage of disease (p < 0.05) and was an independent prognostic factor for NSCLC when adjusted for age and UICC stage (p < 0.001, hazard ratio (HR): 1.888). The constructed nomogram showed a good predictive value. The P53, focal adhesion, and NOD-like receptor signaling pathways were the primary pathways in the high-risk group (adjusted p value <0.05). The high-risk group was correlated with increased immune infiltration (p < 0.05), upregulated relative expression levels of programmed cell death 1 (PD1) (p = 0.015), cytotoxic T-lymphocyte-associated protein 4 (CTLA4) (p = 0.042), higher gene mutation frequency, higher tumor mutational burden (p = 0.034), and better chemotherapy response (p < 0.001). The signature was successfully validated using the GSE26939, GSE31210, GSE30219, and GSE157009 datasets. Dysregulation of these genes in patients with NSCLC was confirmed using the qPCR in an independent cohort (p < 0.05). Conclusion: An RBP-related signature was successfully constructed to predict prognosis in NSCLC, functioning as a reference for individualized therapy, including immunotherapy and chemotherapy.

Systematic Construction and Validation of an RNA Binding Proteins-Based Signature for Prognostic Prediction in Gastric Cancer

Identification of a New RNA-binding Proteins-Based Signature for Prognostic Prediction in Gastric Cancer

Integrating 13 Microarrays to Construct a 6 RNA-binding proteins Prognostic Signature for Gastric Cancer patients

Development and Validation of RNA Binding Protein-Applied Prediction Model for Gastric Cancer.

Development and validation of an RBP gene signature for prognosis prediction in colorectal cancer based on WGCNA

Biological functions and prognostic value of RNA Binding Proteins in clear cell Renal Cell Carcinoma.

Identification and Validation of an RNA Binding Proteins-Associated Prognostic Signature for Non-Small Cell Lung Cancer

A Novel Signature Constructed By Rna-Binding Protein Coding Genes To Improve Overall Survival Prediction Of Glioma Patients

RNA-Binding Protein COL14A1, TNS1, NUSAP1 and YWHAE Are Valid Biomarkers to Predict Peritoneal Metastasis in Gastric Cancer

The prediction of survival in Gastric Cancer based on a Robust 13-Gene Signature

Identification of the Six-RNA-Binding Protein Signature for Prognosis Prediction in Bladder Cancer

Signature based on RNA-binding protein-related genes for predicting prognosis and guiding therapy in non-small cell lung cancer

Construction of an immune-related risk score signature for gastric cancer based on multi-omics data

Transcriptomic signature associated with RNA-binding proteins for survival stratification of laryngeal cancer

GeneExpressScore Signature: a Robust Prognostic and Predictive Classifier in Gastric Cancer

Development of prognostic signature based on RNA binding proteins related genes analysis in clear cell renal cell carcinoma

A Novel RNA Binding Protein-Related Prognostic Signature for Hepatocellular Carcinoma

Development and Validation of a Six-lncRNA Prognostic Signature in Gastric Cancer

Whole Genome Messenger RNA Profiling Identifies a Novel Signature to Predict Gastric Cancer Survival

Development and Validation of a Novel Prognostic Signature in Gastric Adenocarcinoma.

Development and Validation of a Prediction Model for Lung Adenocarcinoma Based on RNA-binding Protein